Plus Therapeutics (PSTV) stock saw a huge rally on Wednesday as the clinical-stage pharmaceutical company received approval from the Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for REYOBIQ.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
This approval covers the use of REYOBIQ as a potential treatment for pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma. The company will conduct a clinical trial of this, with the U.S. Department of Defense providing a $3 million grant to fund the study.
PSTV stock was up 103.69% in pre-market trading on Wednesday, following a 1.47% rally yesterday. However, the shares are down 83.74% year-to-date and have seen much volatility in 2025. This makes the stock a dangerous gambit not fit for risk-averse traders.
Is Plus Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Plus Therapeutics is Strong Buy, based on three Buy and one Hold rating over the past three months. With that comes an average PSTV stock price target of $10, representing a potential 5,247.59% upside for the shares.
